can you take mounjaro and semaglutide together & Tirzepatide: Combine Them? Ozempic vs Mounjaro: Which Medication

P., Cao G

Get access to cutting edge longevity treatments without leaving the couch GLP-1 Injections might be right for you Starting at $160 per kit 400mg of NAD+ Solution per patch Battery powered iontophoresis patch drives NAD+ absorption Improves energy levels, mental clarity & mood Supports DNA health and repair Required to turn off genes that accelerate degenerative aging Administered weekly NAD+ Patches Starting at $160 per kit Starting at $160 per kit 500 or 1,000/mg of NAD+ solution & syringes Improves energy levels, mental clarity & mood Effective in reducing cravings & fatigue Improves post workout recovery More cost-effective & convenient than IV infusions Administered 1-3 times a week NAD+ Injections Starting at $235 per vial Starting at $160 per kit 14 ml bottle with 300 mg/ml NAD+ concentration Improves energy levels, mental clarity & mood Effective in reducing cravings & fatigue Convenient way to boost brain NAD levels Administered as needed NAD+ Nasal Spray Starting at $125 /month Starting at $160 per kit 15 g pump infused with 10% NAD+ concentration Lessens appearance of wrinkles & age spots Improves skin elasticity & firmness Supports DNA health and repair Reduces sun sensitivity & future UV damage Administered daily NAD+ Face Cream Starting at $95 /month NAD+ Face Cream, & NAD+ Patches are temporarily unavailable in AR & MS NAD+ Nasal Spray is currently unavailable in AL & AR NAD+ Injections are temporarily unavailable in AL & CA NEW Injectable GLP-1 Treatments Take charge of your health with a doctor-guided plan if your prescriber deems appropriate

requires careful consideration) Severe gastrointestinal disease (e.g., gastroparesis) Each patient is assessed individually to determine safety and appropriateness 6

Our goal in our program, not forever, is our goal in our program is to reverse metabolic dysfunction

Dual agonists, like Survodutide and Tirzepatide, target two metabolic pathways simultaneously, offering potentially greater efficacy in treating conditions like MASH compared to single-target GLP-1 agonists, which focus on just one pathway